Compare Cassava Sciences Inc (FLNA) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs NEOS S&P 500 High Income ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while NEOS S&P 500 High Income ETF trades at $53.65. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SPYI | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $4.64 | $54.07 |
52-Week Low | $1.09 | $47.98 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
SPYI trades at $53.66, up 0.19% today, with a bullish technical signal from moving averages. The ETF has surpassed $10 billion in assets under management as of June 2026, driven by strong inflows. Recent dividends include $0.52-$0.54 per share, supporting its high-income appeal. The fund's covered-call strategy aims to deliver monthly distributions while retaining partial upside.
Outlook remains positive due to robust investor demand for income solutions, though risks include potential return of capital and fee impact. The ETF's 12% yield attracts retirees, but tax implications and market volatility require careful consideration. Competition with JEPI highlights the need for strategy differentiation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
